These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32448085)

  • 1. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.
    de Oliveira OV; Rocha GB; Paluch AS; Costa LT
    J Biomol Struct Dyn; 2021 Jul; 39(11):3924-3933. PubMed ID: 32448085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
    Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
    J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.
    Chandra A; Gurjar V; Qamar I; Singh N
    J Biomol Struct Dyn; 2021 Aug; 39(12):4201-4211. PubMed ID: 32462970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches.
    Kalhor H; Sadeghi S; Abolhasani H; Kalhor R; Rahimi H
    J Biomol Struct Dyn; 2022 Feb; 40(3):1299-1315. PubMed ID: 32969333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an
    Khan RJ; Jha RK; Singh E; Jain M; Amera GM; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022 Jan; 40(1):438-448. PubMed ID: 32885740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
    Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
    J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment.
    Rahman MM; Saha T; Islam KJ; Suman RH; Biswas S; Rahat EU; Hossen MR; Islam R; Hossain MN; Mamun AA; Khan M; Ali MA; Halim MA
    J Biomol Struct Dyn; 2021 Oct; 39(16):6231-6241. PubMed ID: 32692306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug repurposing for coronavirus (COVID-19):
    Elmezayen AD; Al-Obaidi A; Şahin AT; Yelekçi K
    J Biomol Struct Dyn; 2021 May; 39(8):2980-2992. PubMed ID: 32306862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets.
    Almeida JSFD; Botelho FD; de Souza FR; Dos Santos MC; Goncalves ADS; Rodrigues RLB; Cardozo M; Kitagawa DAS; Vieira LA; Silva RSF; Cavalcante SFA; Bastos LDC; Nogueira MOT; de Santana PIR; Brum JOC; Nepovimova E; Kuca K; LaPlante SR; Galante EBF; Franca TCC
    J Biomol Struct Dyn; 2022 Jul; 40(11):5229-5242. PubMed ID: 33416020
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Ibrahim MAA; Abdelrahman AHM; Hegazy MF
    J Biomol Struct Dyn; 2021 Sep; 39(15):5756-5767. PubMed ID: 32684114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stilbene-based natural compounds as promising drug candidates against COVID-19.
    Wahedi HM; Ahmad S; Abbasi SW
    J Biomol Struct Dyn; 2021 Jun; 39(9):3225-3234. PubMed ID: 32345140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2.
    Peele KA; Kumar V; Parate S; Srirama K; Lee KW; Venkateswarulu TC
    J Pharm Sci; 2021 Jun; 110(6):2346-2354. PubMed ID: 33684397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.
    Fiorucci D; Milletti E; Orofino F; Brizzi A; Mugnaini C; Corelli F
    J Biomol Struct Dyn; 2021 Oct; 39(16):6242-6248. PubMed ID: 32705942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic drug repurposing approach to identify promising inhibitors from FDA-approved drugs against Nsp4 protein of SARS-CoV-2.
    Chakraborty J; Maity A; Sarkar H
    J Biomol Struct Dyn; 2023 Feb; 41(2):550-559. PubMed ID: 34844509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.
    Selvaraj C; Dinesh DC; Panwar U; Abhirami R; Boura E; Singh SK
    J Biomol Struct Dyn; 2021 Aug; 39(13):4582-4593. PubMed ID: 32567979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein.
    Awad IE; Abu-Saleh AAA; Sharma S; Yadav A; Poirier RA
    J Biomol Struct Dyn; 2022 Mar; 40(5):2099-2112. PubMed ID: 33103586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
    Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
    Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.